197 related articles for article (PubMed ID: 27450535)
1. Rational Molecular Design of Potent PLK1 PBD Domain-binding Phosphopeptides Using Preferential Amino Acid Building Blocks.
Mao XL; Wang KF; Zhu F; Pan ZH; Wu GM; Zhu HY
Chem Biodivers; 2016 Aug; 13(8):1103-10. PubMed ID: 27450535
[TBL] [Abstract][Full Text] [Related]
2. Structural and functional analyses of minimal phosphopeptides targeting the polo-box domain of polo-like kinase 1.
Yun SM; Moulaei T; Lim D; Bang JK; Park JE; Shenoy SR; Liu F; Kang YH; Liao C; Soung NK; Lee S; Yoon DY; Lim Y; Lee DH; Otaka A; Appella E; McMahon JB; Nicklaus MC; Burke TR; Yaffe MB; Wlodawer A; Lee KS
Nat Struct Mol Biol; 2009 Aug; 16(8):876-82. PubMed ID: 19597481
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and biological evaluation of phosphopeptides as Polo-like kinase 1 Polo-box domain inhibitors.
Lin TY; Min HP; Jiang C; Niu MM; Yan F; Xu LL; Di B
Bioorg Med Chem; 2018 Jul; 26(12):3429-3437. PubMed ID: 29807699
[TBL] [Abstract][Full Text] [Related]
4. Computational analysis of phosphopeptide binding to the polo-box domain of the mitotic kinase PLK1 using molecular dynamics simulation.
Huggins DJ; McKenzie GJ; Robinson DD; Narváez AJ; Hardwick B; Roberts-Thomson M; Venkitaraman AR; Grant GH; Payne MC
PLoS Comput Biol; 2010 Aug; 6(8):. PubMed ID: 20711360
[TBL] [Abstract][Full Text] [Related]
5. Plk1 activation by Ste20-like kinase (Slk) phosphorylation and polo-box phosphopeptide binding assayed with the substrate translationally controlled tumor protein (TCTP).
Johnson TM; Antrobus R; Johnson LN
Biochemistry; 2008 Mar; 47(12):3688-96. PubMed ID: 18298087
[TBL] [Abstract][Full Text] [Related]
6. Structural analysis of the polo-box domain of human Polo-like kinase 2.
Kim JH; Ku B; Lee KS; Kim SJ
Proteins; 2015 Jul; 83(7):1201-8. PubMed ID: 25846005
[TBL] [Abstract][Full Text] [Related]
7. The molecular basis for phosphodependent substrate targeting and regulation of Plks by the Polo-box domain.
Elia AE; Rellos P; Haire LF; Chao JW; Ivins FJ; Hoepker K; Mohammad D; Cantley LC; Smerdon SJ; Yaffe MB
Cell; 2003 Oct; 115(1):83-95. PubMed ID: 14532005
[TBL] [Abstract][Full Text] [Related]
8. Identification of green tea catechins as potent inhibitors of the polo-box domain of polo-like kinase 1.
Shan HM; Shi Y; Quan J
ChemMedChem; 2015 Jan; 10(1):158-63. PubMed ID: 25196850
[TBL] [Abstract][Full Text] [Related]
9. Molecular and structural basis of polo-like kinase 1 substrate recognition: Implications in centrosomal localization.
García-Alvarez B; de Cárcer G; Ibañez S; Bragado-Nilsson E; Montoya G
Proc Natl Acad Sci U S A; 2007 Feb; 104(9):3107-12. PubMed ID: 17307877
[TBL] [Abstract][Full Text] [Related]
10. Different Plk1 functions show distinct dependencies on Polo-Box domain-mediated targeting.
Hanisch A; Wehner A; Nigg EA; Silljé HH
Mol Biol Cell; 2006 Jan; 17(1):448-59. PubMed ID: 16267267
[TBL] [Abstract][Full Text] [Related]
11. Identification of potential Plk1 targets in a cell-cycle specific proteome through structural dynamics of kinase and Polo box-mediated interactions.
Bibi N; Parveen Z; Rashid S
PLoS One; 2013; 8(8):e70843. PubMed ID: 23967120
[TBL] [Abstract][Full Text] [Related]
12. Non-proteinogenic amino acids in the pThr-2 position of a pentamer peptide that confer high binding affinity for the polo box domain (PBD) of polo-like kinase 1 (Plk1).
Qian WJ; Park JE; Lee KS; Burke TR
Bioorg Med Chem Lett; 2012 Dec; 22(24):7306-8. PubMed ID: 23159568
[TBL] [Abstract][Full Text] [Related]
13. Mono-anionic phosphopeptides produced by unexpected histidine alkylation exhibit high Plk1 polo-box domain-binding affinities and enhanced antiproliferative effects in HeLa cells.
Qian WJ; Park JE; Lim D; Lai CC; Kelley JA; Park SY; Lee KW; Yaffe MB; Lee KS; Burke TR
Biopolymers; 2014 Nov; 102(6):444-55. PubMed ID: 25283071
[TBL] [Abstract][Full Text] [Related]
14. Structural insights into the inhibitor binding and new inhibitor design to Polo-like kinase-1 Polo-box domain using computational studies.
Abdullah M; Guruprasad L
J Biomol Struct Dyn; 2019 Aug; 37(13):3410-3421. PubMed ID: 30146942
[TBL] [Abstract][Full Text] [Related]
15. Proteomic screen finds pSer/pThr-binding domain localizing Plk1 to mitotic substrates.
Elia AE; Cantley LC; Yaffe MB
Science; 2003 Feb; 299(5610):1228-31. PubMed ID: 12595692
[TBL] [Abstract][Full Text] [Related]
16. A high-throughput assay based on fluorescence polarization for inhibitors of the polo-box domain of polo-like kinase 1.
Reindl W; Strebhardt K; Berg T
Anal Biochem; 2008 Dec; 383(2):205-9. PubMed ID: 18793607
[TBL] [Abstract][Full Text] [Related]
17. Polo-box domain: a versatile mediator of polo-like kinase function.
Park JE; Soung NK; Johmura Y; Kang YH; Liao C; Lee KH; Park CH; Nicklaus MC; Lee KS
Cell Mol Life Sci; 2010 Jun; 67(12):1957-70. PubMed ID: 20148280
[TBL] [Abstract][Full Text] [Related]
18. Design and synthesis of a cell-permeable, drug-like small molecule inhibitor targeting the polo-box domain of polo-like kinase 1.
Srinivasrao G; Park JE; Kim S; Ahn M; Cheong C; Nam KY; Gunasekaran P; Hwang E; Kim NH; Shin SY; Lee KS; Ryu E; Bang JK
PLoS One; 2014; 9(9):e107432. PubMed ID: 25211362
[TBL] [Abstract][Full Text] [Related]
19. Modulation of the Allosteric Communication between the Polo-Box Domain and the Catalytic Domain in Plk1 by Small Compounds.
Raab M; Sanhaji M; Pietsch L; Béquignon I; Herbrand AK; Süß E; Gande SL; Caspar B; Kudlinzki D; Saxena K; Sreeramulu S; Schwalbe H; Strebhardt K; Biondi RM
ACS Chem Biol; 2018 Aug; 13(8):1921-1931. PubMed ID: 29927572
[TBL] [Abstract][Full Text] [Related]
20. Molecular and enzoinformatics perspectives of targeting Polo-like kinase 1 in cancer therapy.
Shakil S; Baig MH; Tabrez S; Rizvi SMD; Zaidi SK; Ashraf GM; Ansari SA; Khan AAP; Al-Qahtani MH; Abuzenadah AM; Chaudhary AG
Semin Cancer Biol; 2019 Jun; 56():47-55. PubMed ID: 29122685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]